April, 2023
Read More
The global neurodegenerative disease market size is valued at USD 53.9 billion and will grow at 7.45% annual growth to 2030. The market is characterized by the increasing prevalence of Alzheimer's disease, Parkinson's disease, Multiple sclerosis, Epilepsy, Huntington's disease, Amyotrophic lateral sclerosis, and other conditions. Further, drug sales across hospital pharmacies, retail pharmacy stores, and online pharmacy stores are included.
Neurodegenerative Disease Market Report Statistics
Neurodegenerative Diseases Market Outlook to 2030
Neurodegenerative Diseases Market Analysis, 2023
Neurodegenerative diseases encompass a wide range of conditions where nerve cells in the brain or peripheral nervous systems progressively degenerate over time and ultimately die. Neurodegeneration causes problems with movement and/or cognitive function. The report analyzes the following neurodegenerative diseases-
Of these, Multiple Sclerosis, Alzheimer's and Parkinson's diseases are more prevalent while Huntington's disease and amyotrophic lateral sclerosis are rare diseases. The lack of treatment options presents huge unmet demand for these conditions. Current treatments are largely focused on delaying the progression of the condition, which is largely due to the unknown etiology of the condition.
During 2023, the North American markets had the largest market share worldwide, followed by Europe with a 23.4% market share. Large-scale geriatric population coupled with high healthcare infrastructure are major market drivers. Asia Pacific, on the other hand, has huge potential for market growth with an 8.2% CAGR outlook over the forecast period to 2030.
Despite the launch of new drugs in the past few years, generics continue to penetrate the global market value of neurodegenerative disease therapeutics. Over the forecast period to 2030, the neurodegenerative disease market will register a 7.45% compounded annual growth rate (CAGR) to $89 billion in 2030.
Leading companies operating in the industry include- Boehringer Ingelheim GmbH, Pfizer Inc, Merck & Co. Inc, UCB SA, Novartis AG, and others.
Neurodegenerative Diseases Market Trends- Market characterized by Promising drug pipeline
The neurodegenerative condition is marked by the presence of 98 drug candidates in phase 3 and pre-registration phases worldwide. A total of 81 companies are active in the pipeline (in advanced stages) including large global conglomerates and small research organizations. Collaboration with universities is one of the key trends in the pipeline industry.
Alzheimer’s has 3 drugs in pre-registration and 19 in the phase 3 stage of development. Epilepsy has 19 candidates in advanced stages of development, with 10 drug candidates in pre-registration and 9 in the phase 3 stage.
Four therapeutic candidates are in pre-registration and 14 drug candidates are in Phase 3 for Multiple Sclerosis. Parkinson’s disease has 3 drug candidates in pre-registration and 20 drugs in phase 3. Of 15 drug candidates in development for Amyotrophic Lateral Sclerosis, 2 are in pre-registration, and 13 are in phase 3.
Only one drug candidate- tominersen is in the Phase 3 stage of development for Huntington's Disease. The list of drugs is provided in the analysis by type chapter.
Neurodegenerative Diseases Market Challenges- High Treatment costs associated with the disorders
The financial cost of neurodegenerative disorders to the families of patients and the government is significantly high. For instance, in 2015, the total global societal cost of dementia was estimated to be US$ 818 billion, equivalent to 1.1% of the global gross domestic product. Amyotrophic lateral sclerosis condition in advanced stages can cost around $200,000 per year to the patient. Direct costs of Alzheimer's disease are estimated to be around $250 billion to $300 billion. Such huge costs pose significant financial and emotional challenges to families and the government.
Neurodegenerative Diseases Market Drivers- Orphan drug status and breakthrough therapy designation
Huntington's disease and amyotrophic lateral sclerosis are rare diseases with low prevalence compared to other neurodegenerative conditions. Both the US FDA and EMA recognize these conditions as rare diseases. Due to the small market scope for these conditions, the volume of the pipeline is relatively small. Orphan drug designation is awarded to companies operating in these segments, which gain quick approvals, exemption from regulatory fees, and market exclusivity for longer periods.
Neurodegenerative Diseases Market Segmentation
Alzheimer’s prevalence is estimated to be around 35 million in 2022 and will increase to 50 million in 2030. The condition is highly prevalent among aged adults over 65 years. Diagnosed cases are estimated to be around 30% of total cases.
Alzheimer’s disease is a neurodegenerative disease that worsens with time. The condition starts with changes in the brain that are unnoticeable to the person affected. Initial symptoms such as memory loss, and language problems arising from neurons or nerve cells are damaged or destroyed, causing difficulties in carrying out basic bodily functions.
Alzheimer's disease is the most common form of dementia and can contribute around 60% to 70% of cases (around 50 million people have dementia and every year, there are nearly 10 million new cases of dementia according to the WHO). Alzheimer's disease is characterized as ultimately being fatal. According to the Alzheimer's Facts and Figures Report, the condition costs around $355 billion, including $239 billion in Medicare and Medicaid payments combined in the US alone.
Post-COVID-19 Pandemic Market Recovery Prospects
The COVID-19 pandemic has posed significant challenges to family members and friends who provide care for people with the condition. Adult day programs in many states have been closed, and individuals with the condition are at higher risk due to the severity of their poor memory, significant negative impact on the diagnosis and clinical management of the condition, community, and other challenges faced by patients. However, with recovering COVID conditions, and support from the government and other non-profit organizations, the conditions improved, resulting in the recovery of the market.
Current treatment options for the condition include donepezil, rivastigmine, galantamine, memantine, memantine/donepezil combination, and sodium oligomannate. These therapies are useful largely in early detected cases. In 2020, the US FDA approved an IND application for sodium oligomannurarate in Alzheimer's disease. However, the absence of drugs that can modify disease progression will limit the scope of growth.
The market size for Alzheimer’s disease therapeutics is estimated at $4.6 billion. Over the forecast period to 2028, the market will register 14.6% CAGR growth, primarily driven by the anticipated launch of aducanumab (Biogen), Lecanemab (Eisai Co Ltd), and gantenerumab (F. Hoffmann-La Roche Ltd).
Neurodegenerative Diseases Market Segmentation
Types
Applications
Regions
Neurodegenerative Diseases Market Companies Profiled in the Report-
1. Executive Summary
1.1 Introduction to Neurodegenerative Disease Markets
1.2 Neurodegenerative Disease Market Size Outlook, 2021- 2030
1.3 Growth Opportunities in Neurodegenerative Disease Industry
1.4 Winning Strategies for the post-pandemic future
2. Report Guide
2.1 Market Definition and Scope
2.2 Market Segmentation
2.3 Research Methodology
2.4 Forecast Methodology
2.5 List of Abbreviations
3. Growth Opportunity Analysis
3.1 Key Neurodegenerative Disease Market Trends
3.1.1 Market characterized by Promising drug pipeline through 2030
3.1.2 Increase in prevalence of neurological disorders drives the market demand
3.1.3 Focus on emerging countries remains a major marketing strategy for expansion
3.2 Key Neurodegenerative Disease Market Growth Drivers
3.2.1 Unmet medical needs drives investments in R&D
3.2.2 Orphan drug status and breakthrough therapy designation
3.2.3 Increasing Healthcare Expenditure worldwide
3.3 Key Neurodegenerative Disease Market Growth Restraints
3.3.1 High Treatment costs associated with the disorders
3.3.2 Intense competitive conditions
4 Neurodegenerative Disease Market Outlook – Scenario Analysis
4.1 Low Growth Case Scenario Forecasts: Neurodegenerative Disease Market Size Outlook to 2030
4.2 Reference Growth Case Scenario Forecasts: Neurodegenerative Disease Market Size Outlook to 2030
4.3 High Growth Case Scenario Forecasts: Neurodegenerative Disease Market Size Outlook to 2030
5. Neurodegenerative Disease Market Segmentation- Outlook by Type
5.1 Neurodegenerative Disease Market Share Analysis by Type, 2023
5.2 Alzheimer’s Disease Market Outlook to 2030
5.3 Multiple Sclerosis Disease Market Outlook to 2030
5.4 Epilepsy Market Outlook to 2030
5.5 Huntington’s Disease Market Outlook to 2030
5.6 Amyotrophic Lateral Sclerosis Market Outlook to 2030
7. Neurodegenerative Disease Market Segmentation- Outlook by End-Use Industry
7.1 Neurodegenerative Disease Market Share Analysis by End-Use Industry, 2023
7.2 Hospital Pharmacy: Neurodegenerative Disease Market Revenue Outlook to 2030
7.3 Retail Pharmacy: Neurodegenerative Disease Market Revenue Outlook to 2030
7.4 Online Pharmacy: Neurodegenerative Disease Market Revenue Outlook to 2030
8. North America Neurodegenerative Disease Market Outlook and Opportunities to 2030
8.1 Market Snapshot, 2023
8.2 North America Neurodegenerative Disease Market Growth Opportunities
8.2.1 North America Neurodegenerative Disease Market Outlook by Type, 2021 to 2030
8.2.3 North America Neurodegenerative Disease Market Outlook by End-User Industry, 2021 to 2030
8.2.4 North America Neurodegenerative Disease Market Outlook by Country, 2021 to 2030
8.3 United States Neurodegenerative Disease Market Outlook, 2021 to 2030
8.4 Canada Neurodegenerative Disease Market Outlook, 2021 to 2030
8.5 Mexico Neurodegenerative Disease Market Outlook, 2021 to 2030
9. Europe Neurodegenerative Disease Market Outlook and Opportunities to 2030
9.1 Market Snapshot, 2023
9.2 Europe Neurodegenerative Disease Market Growth Opportunities
9.2.1 Europe Neurodegenerative Disease Market Outlook by Type, 2021 to 2030
9.2.3 Europe Neurodegenerative Disease Market Outlook by End-User Industry, 2021 to 2030
9.2.4 Europe Neurodegenerative Disease Market Outlook by Country, 2021 to 2030
9.3 Germany Neurodegenerative Disease Market Outlook, 2021 to 2030
9.4 France Neurodegenerative Disease Market Outlook, 2021 to 2030
9.5 United Kingdom Neurodegenerative Disease Market Outlook, 2021 to 2030
9.6 Spain Neurodegenerative Disease Market Outlook, 2021 to 2030
9.7 Italy Neurodegenerative Disease Market Outlook, 2021 to 2030
9.8 Other Europe Neurodegenerative Disease Market Outlook, 2021 to 2030
10. Asia Pacific Neurodegenerative Disease Market Outlook and Opportunities to 2030
10.1 Market Snapshot, 2023
10.2 Asia Pacific Neurodegenerative Disease Market Growth Opportunities
10.2.1 Asia Pacific Neurodegenerative Disease Market Outlook by Type, 2021 to 2030
10.2.3 Asia Pacific Neurodegenerative Disease Market Outlook by End-User Industry, 2021 to 2030
10.2.4 Asia Pacific Neurodegenerative Disease Market Outlook by Country, 2021 to 2030
10.3 China Neurodegenerative Disease Market Outlook, 2021 to 2030
10.4 Japan Neurodegenerative Disease Market Outlook, 2021 to 2030
10.5 India Neurodegenerative Disease Market Outlook, 2021 to 2030
10.6 South Korea Neurodegenerative Disease Market Outlook, 2021 to 2030
10.7 Indonesia Neurodegenerative Disease Market Outlook, 2021 to 2030
10.8 Other Asia Pacific Neurodegenerative Disease Market Outlook, 2021 to 2030
11. South and Central America Neurodegenerative Disease Market Outlook and Opportunities to 2030
11.1 Market Snapshot, 2023
11.2 South and Central America Neurodegenerative Disease Market Growth Opportunities
11.2.1 South and Central America Neurodegenerative Disease Market Outlook by Type, 2021 to 2030
11.2.3 South and Central America Neurodegenerative Disease Market Outlook by End-User Industry, 2021 to 2030
11.2.4 South and Central America Neurodegenerative Disease Market Outlook by Country, 2021 to 2030
11.3 Brazil Neurodegenerative Disease Market Outlook, 2021 to 2030
11.4 Argentina Neurodegenerative Disease Market Outlook, 2021 to 2030
11.5 Other Latin America Neurodegenerative Disease Market Outlook, 2021 to 2030
12. Middle East and Africa Neurodegenerative Disease Market Outlook and Opportunities to 2030
12.1 Market Snapshot, 2023
12.2 Middle East and Africa Neurodegenerative Disease Market Growth Opportunities
12.2.1 Middle East and Africa Neurodegenerative Disease Market Outlook by Type, 2021 to 2030
12.2.3 Middle East and Africa Neurodegenerative Disease Market Outlook by End-User Industry, 2021 to 2030
12.2.4 Middle East and Africa Neurodegenerative Disease Market Outlook by Country, 2021 to 2030
12.3 Saudi Arabia Neurodegenerative Disease Market Outlook, 2021 to 2030
12.4 United Arab Emirates (the UAE) Neurodegenerative Disease Market Outlook, 2021 to 2030
12.5 Other Middle East Neurodegenerative Disease Market Outlook, 2021 to 2030
12.6 Egypt Neurodegenerative Disease Market Outlook, 2021 to 2030
12.7 South Africa Neurodegenerative Disease Market Outlook, 2021 to 2030
12.8 Other Africa Neurodegenerative Disease Market Outlook, 2021 to 2030
13. Profiles of major world Neurodegenerative Disease Companies
13.1 Boehringer Ingelheim GmbH
- Key Statistics
- Business Operations
- Products and Services Offered
- SWOT Analysis
- Financial Profile
13.2 Pfizer Inc.
- Key Statistics
- Business Operations
- Products and Services Offered
- SWOT Analysis
- Financial Profile
13.3 Merck & Co. Inc
- Key Statistics
- Business Operations
- Products and Services Offered
- SWOT Analysis
- Financial Profile
13.4 UCB SA
- Key Statistics
- Business Operations
- Products and Services Offered
- SWOT Analysis
- Financial Profile
13.5 Novartis AG
- Key Statistics
- Business Operations
- Products and Services Offered
- SWOT Analysis
- Financial Profile
13.6 Abbvie Inc
- Key Statistics
- Business Operations
- Products and Services Offered
- SWOT Analysis
- Financial Profile
13.7 Teva Pharmaceuticals
- Key Statistics
- Business Operations
- Products and Services Offered
- SWOT Analysis
- Financial Profile
13.8 Sanofi
- Key Statistics
- Business Operations
- Products and Services Offered
- SWOT Analysis
- Financial Profile
13.9 Biogen Inc
- Key Statistics
- Business Operations
- Products and Services Offered
- SWOT Analysis
- Financial Profile
13.10 Johnson and Johnson
- Key Statistics
- Business Operations
- Products and Services Offered
- SWOT Analysis
- Financial Profile
14. Appendix
14.1 Publisher’s Expertise
14.2 List of Tables and Charts
14.3 List of Exhibits
14.4 Legal Disclaimer
Unmet medical needs drives R&D investments, Promising drug pipeline through 2030, Increase in prevalence of neurological disorders, Focus on emerging countries, Increasing global Healthcare Expenditure, Orphan drug status and breakthrough therapy designations
The neurodegenerative disease market size stood at $53.9 billion in 2023
The neurodegenerative disease market is poised to grow at a compounded annual growth rate of 7.45% over the forecast period to 2023
Leading companies operating in neurodegenerative disease industry including Boehringer Ingelheim GmbH, Pfizer Inc, Merck & Co. Inc, UCB SA, Novartis AG, Abbvie Inc, Teva Pharmaceuticals, Sanofi, Biogen Inc, Johnson and Johnson
Multiple Sclerosis is the leading disease type contributing to the highest revenue in neurodegenerative diseases. Other neurodegenerative disease types analysed in the report include Alzheimer’s Disease, Parkinson’s Disease, Epilepsy, Huntington’s Disease, and Amyotrophic Lateral Sclerosis